Switch theme
Sign up to access all valuation multiples
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
2015
n/a
LTM Revenue $14.3M
Last FY EBITDA -$97.0M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chongqing Genrix has a last 12-month revenue (LTM) of $14.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Chongqing Genrix achieved revenue of $4.2M and an EBITDA of -$97.0M.
Chongqing Genrix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chongqing Genrix valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $14.3M | XXX | $4.2M | XXX | XXX | XXX |
| Gross Profit | $12.1M | XXX | $3.4M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$97.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2322% | XXX | XXX | XXX |
| EBIT | -$103M | XXX | -$116M | XXX | XXX | XXX |
| EBIT Margin | -724% | XXX | -2778% | XXX | XXX | XXX |
| Net Profit | -$103M | XXX | -$111M | XXX | XXX | XXX |
| Net Margin | -724% | XXX | -2649% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Chongqing Genrix's stock price is CNY 30 (or $4).
Chongqing Genrix has current market cap of CNY 10.9B (or $1.5B), and EV of CNY 9.4B (or $1.3B).
See Chongqing Genrix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.5B | XXX | XXX | XXX | XXX | $-0.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Chongqing Genrix has market cap of $1.5B and EV of $1.3B.
Chongqing Genrix's trades at 313.1x EV/Revenue multiple, and -13.5x EV/EBITDA.
Equity research analysts estimate Chongqing Genrix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chongqing Genrix has a P/E ratio of -14.6x.
See valuation multiples for Chongqing Genrix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 91.6x | XXX | 313.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -13.5x | XXX | XXX | XXX |
| EV/EBIT | -12.7x | XXX | -11.3x | XXX | XXX | XXX |
| EV/Gross Profit | 108.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -14.6x | XXX | -13.7x | XXX | XXX | XXX |
| EV/FCF | -12.1x | XXX | -15.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChongqing Genrix's last 12 month revenue growth is 223%
Chongqing Genrix's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Chongqing Genrix's rule of 40 is -58148% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chongqing Genrix's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Chongqing Genrix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 223% | XXX | 312% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2322% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -58148% | XXX | -2099% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 156% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2026% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2860% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chongqing Genrix acquired XXX companies to date.
Last acquisition by Chongqing Genrix was XXXXXXXX, XXXXX XXXXX XXXXXX . Chongqing Genrix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Chongqing Genrix founded? | Chongqing Genrix was founded in 2015. |
| Where is Chongqing Genrix headquartered? | Chongqing Genrix is headquartered in China. |
| Is Chongqing Genrix publicy listed? | Yes, Chongqing Genrix is a public company listed on SHG. |
| What is the stock symbol of Chongqing Genrix? | Chongqing Genrix trades under 688443 ticker. |
| When did Chongqing Genrix go public? | Chongqing Genrix went public in 2023. |
| Who are competitors of Chongqing Genrix? | Similar companies to Chongqing Genrix include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Chongqing Genrix? | Chongqing Genrix's current market cap is $1.5B |
| What is the current revenue of Chongqing Genrix? | Chongqing Genrix's last 12 months revenue is $14.3M. |
| What is the current revenue growth of Chongqing Genrix? | Chongqing Genrix revenue growth (NTM/LTM) is 223%. |
| What is the current EV/Revenue multiple of Chongqing Genrix? | Current revenue multiple of Chongqing Genrix is 91.6x. |
| Is Chongqing Genrix profitable? | Yes, Chongqing Genrix is EBITDA-positive (as of the last 12 months). |
| What is the current FCF of Chongqing Genrix? | Chongqing Genrix's last 12 months FCF is -$108M. |
| What is Chongqing Genrix's FCF margin? | Chongqing Genrix's last 12 months FCF margin is -759%. |
| What is the current EV/FCF multiple of Chongqing Genrix? | Current FCF multiple of Chongqing Genrix is -12.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
